GLP-1 appetite prompts dental warning

A snapshot found one-in-five Australians would consider using GLP-1s, as new national figures show rising overweight and obesity rates The growing popularity of glucagon-like peptide-1 receptor agonists (GLP-1s) has triggered a dental reminder about the potential side effects of the diabetes and weight management medications. A survey from health insurer Bupa found 20% of Australians